91 related articles for article (PubMed ID: 20307138)
1. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism.
Al Koudsi N; Tyndale RF
Xenobiotica; 2010 Jun; 40(6):381-92. PubMed ID: 20307138
[TBL] [Abstract][Full Text] [Related]
2. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.
Al Koudsi N; Hoffmann EB; Assadzadeh A; Tyndale RF
Eur J Clin Pharmacol; 2010 Mar; 66(3):239-51. PubMed ID: 20012030
[TBL] [Abstract][Full Text] [Related]
3. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys.
Ferguson CS; Miksys S; Palmour RM; Tyndale RF
J Pharmacol Exp Ther; 2012 Dec; 343(3):628-37. PubMed ID: 22935730
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo.
Liu Z; Li L; Wu H; Hu J; Ma J; Zhang QY; Ding X
Drug Metab Dispos; 2015 Feb; 43(2):208-16. PubMed ID: 25409894
[TBL] [Abstract][Full Text] [Related]
6. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
7. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
Binnington MJ; Zhu AZ; Renner CC; Lanier AP; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2012 Jun; 22(6):429-40. PubMed ID: 22569203
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.
Lee AM; Jepson C; Shields PG; Benowitz N; Lerman C; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1312-4. PubMed ID: 17548706
[No Abstract] [Full Text] [Related]
9. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.
Xie HJ; Yasar U; Lundgren S; Griskevicius L; Terelius Y; Hassan M; Rane A
Pharmacogenomics J; 2003; 3(1):53-61. PubMed ID: 12629583
[TBL] [Abstract][Full Text] [Related]
10. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
[TBL] [Abstract][Full Text] [Related]
11. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.
Miksys S; Lerman C; Shields PG; Mash DC; Tyndale RF
Neuropharmacology; 2003 Jul; 45(1):122-32. PubMed ID: 12814665
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility.
Berköz M; Yalin S
Leuk Res; 2009 Jul; 33(7):919-23. PubMed ID: 19144407
[TBL] [Abstract][Full Text] [Related]
13. [Cyclophosphamide and CYP2B6].
Torimoto Y; Kohgo Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1090-3. PubMed ID: 18633247
[TBL] [Abstract][Full Text] [Related]
14. ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: implications in hepatic stress responses.
Pascual M; Gómez-Lechón MJ; Castell JV; Jover R
Drug Metab Dispos; 2008 Jun; 36(6):1063-72. PubMed ID: 18332083
[TBL] [Abstract][Full Text] [Related]
15. Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.
Lee AM; Miksys S; Tyndale RF
Br J Pharmacol; 2006 Jul; 148(6):786-94. PubMed ID: 16751792
[TBL] [Abstract][Full Text] [Related]
16. Oxidative metabolism of BDE-99 by human liver microsomes: predominant role of CYP2B6.
Erratico CA; Szeitz A; Bandiera SM
Toxicol Sci; 2012 Oct; 129(2):280-92. PubMed ID: 22738989
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
Xie H; Griskevicius L; Ståhle L; Hassan Z; Yasar U; Rane A; Broberg U; Kimby E; Hassan M
Eur J Pharm Sci; 2006 Jan; 27(1):54-61. PubMed ID: 16183265
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).
Watanabe T; Sakuyama K; Sasaki T; Ishii Y; Ishikawa M; Hirasawa N; Hiratsuka M
Pharmacogenet Genomics; 2010 Jul; 20(7):459-62. PubMed ID: 20517174
[TBL] [Abstract][Full Text] [Related]
19. Human CYP2B6: expression, inducibility and catalytic activities.
Gervot L; Rochat B; Gautier JC; Bohnenstengel F; Kroemer H; de Berardinis V; Martin H; Beaune P; de Waziers I
Pharmacogenetics; 1999 Jun; 9(3):295-306. PubMed ID: 10471061
[TBL] [Abstract][Full Text] [Related]
20. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.
Yuan ZH; Liu Q; Zhang Y; Liu HX; Zhao J; Zhu P
Ann Hematol; 2011 Mar; 90(3):293-9. PubMed ID: 20878158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
